Provided by Tiger Trade Technology Pte. Ltd.

Phasebio Pharmaceuticals Inc

0.0701
0.0000
Volume:- -
Turnover:- -
Market Cap:3.50M
PE:-0.03
High:0.0701
Open:0.0701
Low:0.0701
Close:0.0701
52wk High:1.38
52wk Low:0.0665
Shares:49.86M
Float Shares:34.41M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1189
EPS(LYR):-2.9844
ROE:-3091.02%
ROA:-106.07%
PB:-0.03
PE(LYR):-0.02

Loading ...

Company Profile

Company Name:
Phasebio Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.